Validation study of new febrile neutropenia guideline-Comparative study between oral levofloxacin and parenteral cefepime in low-risk patients with febrile neutropenia
Phase 3
- Conditions
- Febrile neutropenia
- Registration Number
- JPRN-C000000396
- Lead Sponsor
- Japan Febrile Neutropenia Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Poor-risk acute leukemia patients Isolation of microorganism resistant to the study drugs Past history of allergy to beta-lactum or study drugs Pregnant or lactating woman Age of 15 years or younger Antimicrobial treatment within 3 months prior to the study entry Allegenic hematopoietic stem cell transplantation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment efficacy at 7 days after antimicrobiral therapy
- Secondary Outcome Measures
Name Time Method Adverse events, treatment results in 3-5 days after the start of therapy, succes rate as an outpatient, survival, antibacterial effect